GlassScriptPhysician profile
Katherine Langlais
NPI 1689299687
$5,826.02
in general payments reported to CMS, 2019-2025
22 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $805 · 2023: $576 · 2024: $1,839 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,477 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.71 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $2,116.79 | 2021-2025 | Remodulin, Remodulin, Orenitram |
| Astellas Pharma US INC | $679.47 | 2021-2025 | Cresemba |
| Actelion Pharmaceuticals US, INC. | $633.60 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.12 | 2022-2025 | Ofev, Jascayd |
| Ani Pharmaceuticals, INC. | $471.24 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $245.04 | 2022-2023 | Xarelto |
| Shionogi INC | $211.03 | 2023-2024 | Fetroja |
| Mallinckrodt Hospital Products INC. | $208.67 | 2023-2025 | Acthar |
| Genentech, INC. | $158.22 | 2021-2023 | Pulmozyme |
| Takeda Pharmaceuticals U.S.A., INC. | $111.22 | 2022-2025 | Livtencity |
| Merck Sharp & Dohme LLC | $95.66 | 2025 | Winrevair |
| Vertex Pharmaceuticals Incorporated | $49.05 | 2024-2025 | |
| Melinta Therapeutics, LLC | $47.29 | 2023 | Kimyrsa, Vabomere, Rezzayo |
| Zambon USA LTD. | $42.00 | 2024 | |
| Mylan Specialty L.P. | $40.39 | 2022-2024 | Tobi Podhaler |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $35.03 | 2024 | Envarsus |
| Chiesi USA, INC. | $24.87 | 2023 | Bronchitol |
| Csl Behring | $20.63 | 2024 | Kcentra |
| Atricure, INC. | $19.32 | 2023 | |
| Getinge USA Sales, LLC | $17.39 | 2023 | Cardiohelp |
| Baxter Healthcare | $13.92 | 2023 | Hillrom - Life 2000 Ventilation System |
| Gilead Sciences, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Langlais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.